Nevertheless, the above analysis suggests that many of the genes that were identified as markers of lapatinib insensitivity in T47D and MDA-MB-468 cells, can indeed be generally used as markers of BC cell response to a variety of HER2 and/or EGFR targeted therapies. Here, EGFR is linked to breast cancer.